Innate Historical Cash Flow
| IPHA Stock | USD 1.54 0.04 2.67% |
Analysis of Innate Pharma cash flow over time is an excellent tool to project Innate Pharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 375.2 K or Depreciation of 9 M as it is a great indicator of Innate Pharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Innate Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Innate Pharma is a good buy for the upcoming year.
Innate |
About Innate Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Innate balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Innate's non-liquid assets can be easily converted into cash.
Innate Pharma Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Innate Pharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Innate Pharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.At present, Innate Pharma's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's End Period Cash Flow is expected to grow to about 84.5 M, whereas Change In Cash is projected to grow to (12.9 M).
Innate Pharma cash flow statement Correlations
Click cells to compare fundamentals
Innate Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Innate Pharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 50.6M | (66.1M) | (33.0M) | (19.5M) | (13.6M) | (12.9M) | |
| Stock Based Compensation | 3.8M | 2.5M | 2.6M | 4.2M | 4.3M | 2.4M | |
| Free Cash Flow | (30.5M) | (63.1M) | (59.8M) | (20.3M) | (34.9M) | (33.2M) | |
| Change In Working Capital | 40.2M | (49.2M) | (9.9M) | (12.5M) | (32.1M) | (30.5M) | |
| Begin Period Cash Flow | 152.3M | 202.9M | 136.8M | 103.8M | 84.2M | 81.0M | |
| Other Cashflows From Financing Activities | 13.7M | (251K) | 188K | 1.9M | 395K | 375.3K | |
| Depreciation | 16.5M | 56.8M | 4.6M | 45.4M | 5.1M | 9.0M | |
| Other Non Cash Items | (774K) | (544K) | (1.3M) | 1.8M | (2.2M) | (2.1M) | |
| Capital Expenditures | 65.4M | 11.3M | 1.3M | 1.1M | 2.4M | 2.2M | |
| Total Cash From Operating Activities | 34.9M | (51.8M) | (58.5M) | (19.2M) | (32.6M) | (30.9M) | |
| Net Income | (20.8M) | (64.0M) | (52.8M) | (58.1M) | (7.6M) | (7.9M) | |
| Total Cash From Financing Activities | 77.8M | (1.1M) | 26.8M | (1.8M) | (2.0M) | (1.9M) | |
| End Period Cash Flow | 202.9M | 136.8M | 103.8M | 84.2M | 70.6M | 84.5M | |
| Change To Account Receivables | 110.3M | (22.9M) | 3.4M | (4.2M) | (13.7M) | (13.0M) | |
| Investments | (62.1M) | (13.4M) | (917K) | 1.9M | 20.6M | 21.7M | |
| Net Borrowings | 11.9M | (844K) | 26.6M | (2.0M) | (2.3M) | (2.2M) | |
| Total Cashflows From Investing Activities | (62.1M) | (13.4M) | (917K) | 1.9M | 2.2M | 2.3M | |
| Change To Operating Activities | (10.4M) | (49.2M) | (9.9M) | (12.5M) | (11.3M) | (10.7M) | |
| Other Cashflows From Investing Activities | 1.3M | 903K | 406K | (1K) | (900.0) | (855.0) | |
| Change To Netincome | (1.1M) | 4.6M | (360K) | 6.0M | 7.0M | 7.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.